Curocell announced encouraging updates on the next-generation anti-CD19 CAR-T, Anbalcabtagene-autoleucel at International Conference on Malignant Lymphoma (ICML) 2023
/PRNewswire/ -- Curocell Inc, a Korea-based clinical-stage CAR-T cell therapy company, announced updated Phase 2 interim results for Anbalcabtagene-autoleucel...
Source: prnewswire.com